SK Capital’s investment will serve as a catalyst for a new strategic direction as the Company seeks to deepen and expand its presence in fine chemistries for the global life science market.
The virtual event will be attended by representatives from state & district health administration, corporates, industries, civil society, and NGOs as the country reiterates its commitment towards TB elimination by 2025
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
NCDC branches in States/UTs will provide a boost to Public Health Infrastructurewith prompt surveillance, rapid detection and timely monitoring of diseases enabling Early Interventions
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
The purpose of the conclave was to discuss the present situation of body-organ-eye donation in India and find solutions to the challenges ahead in future
The capital expansion program commenced in June 2022 and is expected to complete in 2024
The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly
The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools
Subscribe To Our Newsletter & Stay Updated
